Ability of Donor CD8 Cells to Prevent Rejection of Marrow in Recipients With MHC Class I Disparity
| Day . | CD8 Cells Added . | Percentage of Donor Marrow-Derived Cells . | |
|---|---|---|---|
| T Lymphocytes . | Granulocytes . | ||
| 28 | None | 1, 0, 1, 0, 0 | 3, 2, 2, 4, 1 |
| 5.0 × 104 | 39, 89, 0, 1, 1 | 96, 99, 2, 6, 3 | |
| 2.0 × 105 | 88, 0, 94, 89, 94 | 100, 2, 99, 99, 99 | |
| 8.0 × 105 | 89, 87, 89, 86, 80 | 100, 100, 98, 100, 100 | |
| 61 | None | 0, 0, 0, 3, 1 | 1, 0, 1, 3, 2 |
| 5.0 × 104 | 72, 99, 0, 0, 0 | 93, 94, 0, 1, 1 | |
| 2.0 × 105 | 89, 3, 99, 89 | 71, 4, 96, 79 | |
| 8.0 × 105 | 99, 94, 84, 92, 96 | 99, 86, 73, 86, 90 | |
| 98 | None | 0, 0, 3, 1, 1 | 1, 2, 7, 2, 3 |
| 5.0 × 104 | 92, 99, 1, 0, 2 | 78, 97, 3, 2, 4 | |
| 2.0 × 105 | 99, 0, 99, 99 | 97, 1, 97, 99 | |
| 8.0 × 105 | 97, 98, 100, 99, 99 | 99, 100, 99, 100, 98 | |
| Day . | CD8 Cells Added . | Percentage of Donor Marrow-Derived Cells . | |
|---|---|---|---|
| T Lymphocytes . | Granulocytes . | ||
| 28 | None | 1, 0, 1, 0, 0 | 3, 2, 2, 4, 1 |
| 5.0 × 104 | 39, 89, 0, 1, 1 | 96, 99, 2, 6, 3 | |
| 2.0 × 105 | 88, 0, 94, 89, 94 | 100, 2, 99, 99, 99 | |
| 8.0 × 105 | 89, 87, 89, 86, 80 | 100, 100, 98, 100, 100 | |
| 61 | None | 0, 0, 0, 3, 1 | 1, 0, 1, 3, 2 |
| 5.0 × 104 | 72, 99, 0, 0, 0 | 93, 94, 0, 1, 1 | |
| 2.0 × 105 | 89, 3, 99, 89 | 71, 4, 96, 79 | |
| 8.0 × 105 | 99, 94, 84, 92, 96 | 99, 86, 73, 86, 90 | |
| 98 | None | 0, 0, 3, 1, 1 | 1, 2, 7, 2, 3 |
| 5.0 × 104 | 92, 99, 1, 0, 2 | 78, 97, 3, 2, 4 | |
| 2.0 × 105 | 99, 0, 99, 99 | 97, 1, 97, 99 | |
| 8.0 × 105 | 97, 98, 100, 99, 99 | 99, 100, 99, 100, 98 | |
Groups of 5 irradiated (550 cGy) bm1 (Ly5.2) recipients were transplanted with 5.0 × 106 T-cell–depleted B6-Ly5.1 marrow cells alone or with the indicated numbers of B6 (Ly5.2) CD8-enriched LN cells added to the graft. The percentage of donor marrow-derived T cells and granulocytes in the peripheral blood of recipients surviving on days 28, 61, and 97 after transplantation was determined by two-color staining with CD3- and Ly5.1-specific antibodies. Data indicate results for individual recipients.